HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

YSL Beaute Q3 sales

This article was originally published in The Rose Sheet

Executive Summary

Yves Saint Laurent Nu women's fragrance has "performed exceptionally well" since debuting in October, but increased advertising to support the launch and to enhance the YSL image led to lower profitability in the quarter, parent Gucci announces Dec. 18. Communication and selling expenses were 22% and 20% of sales, respectively, compared to 15% and 13% the prior year period. YSL Beaute operating profit before goodwill and amortization was $20.5 mil. in the quarter, down 48.5%, Gucci says. Third quarter YSL Beaute revenues were $138.8 mil., down 14.3%, due to lower U.S. and travel retail sales. Nu was first YSL fragrance to debut under control of creative director Tom Ford (1"The Rose Sheet" July 16, p. 4). Consolidated Gucci Group sales fell 7.9% to $566.2 mil. in Q3, while net income plummeted 50.7% to $56.3 mil...

You may also be interested in...



The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.

Mallinckrodt Finds An Exit Door For Generics In Proposed Opioid Settlement

The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately. 

UsernamePublicRestriction

Register

RS009915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel